To improve the toolbox available to evaluate seasonal flu vaccines, European public and private research institutions are joining together in FLUCOP, a 13,9M€ project funded by the Innovative Medicines Initiative (IMI). Please follow the link for reading the full press release.
The FLUCOP flyer shows the project at a quick glance: FLUCOP_Flyer
Freidl GS, van den Ham HJ, Boni MF, de Bruin E, Koopmans MP. Changes in heterosubtypic antibody responses during the first year of the 2009 A(H1N1) influenza pandemic. Sci Rep. 6:20385. doi: 10.1038/srep20385, 2016 Feb 8.
Mohn KG, Cox RJ1, Tunheim G, Berdal JE, Hauge AG, Jul-Larsen Å; Norwegian Pandemic Group, Peters B, Oftung F, Jonassen CM, Mjaaland S5. Immune Responses in Acute and Convalescent Patients with Mild, Moderate and Severe Disease during the 2009 Influenza Pandemic in Norway. PLoS One 10(11):e0143281. doi: 10.1371/journal.pone.0143281. eCollection 2015, 2015 Nov 25.
Lartey S, Pathirana RD, Zhou F, Jul-Larsen Å, Montomoli E, Wood J, Cox RJ. Single dose vaccination of the ASO3-adjuvanted A(H1N1)pdm09 monovalent vaccine in health care workers elicits homologous and cross-reactive cellular and humoral responses to H1N1 strains. Hum. Vaccin. Immunother. 2015;11(7):1654-62. doi: 10.1080/21645515.2015.1048939, 2015 May 26.
Sridhar S, Brokstad KA, Cox RJ. Influenza Vaccination Strategies: Comparing Inactivated and Live Attenuated Influenza Vaccines. Vaccines (Basel) 3(2):373-89. doi: 10.3390/vaccines3020373, 2015 Apr 24.